CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 320 target
Drug / intervention
PF-07248144 +5 moredrug
Likely dose
Not stated in record
Key inclusion· 13
  • ✓Histological or cytological diagnosis of locally advanced or metastatic ER+HER2- breast cancer
  • ✓Part 1A: intolerant or resistant to standard therapy or no standard therapy available
  • ✓Part 1B-1E: progressed after at least 1 prior line of endocrine therapy and CDK4/6 inhibitor
  • ✓Part 2A: progressed after at least 1 prior line CDK4/6 inhibitor and endocrine therapy
Key exclusion· 9
  • ✕Unmanageable ascites
  • ✕Any other active malignancy within 3 years except basal cell/squamous cell skin cancer or carcinoma in situ
  • ✕Major surgery, radiation, or systemic anti-cancer therapy within 3 weeks
  • ✕Prior irradiation to >25% of bone marrow

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04606446
NCT04606446Phase 2RecruitingOn TrackUpdated 2mo ago
Long Recruiting
CompareCT.gov

A PHASE 1/2A DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTI-TUMOR ACTIVITY OF PF-07248144 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS

Pfizer·interventional·Posted Oct 28, 2020·Updated Apr 16, 2026

In Brief

A Phase 2 clinical trial evaluating PF-07248144, Fulvestrant, and 4 other interventions for Locally Advanced or Metastatic ER+ HER2- Breast Cancer and 2 related conditions. Currently recruiting, targeting 320 participants across 44 sites in 5 countries.

Detailed Summary

This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a single agent and in combination with other agents

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLocally Advanced or Metastatic ER+ HER2- Breast Cancer, Locally Advanced or Metastatic Castration-resistant Prostate Cancer, Locally Advanced or Metastatic Non-small Cell Lung Cancer
CountriesAustralia, China, Japan, South Korea, United States
Collaborators--

Timeline

Phase 2Recruiting
202120222023202420252026202720282029
First PostedOct 28, 2020
Enrollment StartNov 16, 2020
Primary CompletionJul 13, 2029
Study CompletionAug 10, 2029
TodayJul 2, 2026
Enrollment to primary: 8.7 yearsPosted 5.7 years agoPrimary completion in 3.0 years

Interventions

PF-07248144drug

KAT6 Inhibitor

Fulvestrantdrug

Endocrine Therapy

Letrozoledrug

Endocrine Therapy

Palbociclibdrug

CDK4/6 Inhibitor

PF-07220060drug

CDK4 inhibitor

PF-07850327, ARV-471, vepdegestrantdrug

PROTAC (PROteolysis Targeting Chimera) ER degrader